Wegovy is FDA-approved for weight management, not for treating diabetes. The same active ingredient, semaglutide, is sold under a different brand name, Ozempic, for type 2 diabetes. This distinction confuses many people because both medications work the same way and come from the same manufacturer, but they carry different approvals, different dosages, and different price structures.
What Wegovy Is Approved For
The FDA has approved Wegovy for three distinct purposes, all related to weight and its consequences rather than blood sugar control. First, it’s approved for long-term weight reduction in adults and adolescents 12 and older with obesity (a BMI of 30 or above), and in adults with a BMI of 27 to 29.9 who also have at least one weight-related health condition. Second, it’s approved to reduce the risk of heart attack, stroke, and cardiovascular death in adults who already have heart disease and are living with obesity or overweight. Third, it recently gained approval for a type of fatty liver disease with moderate to advanced scarring.
None of these indications mention type 2 diabetes as a treatment target. That said, people with type 2 diabetes or prediabetes can still be prescribed Wegovy for weight management if they meet the BMI criteria. Losing weight often improves blood sugar control as a secondary benefit, but the prescription itself is for the weight, not the diabetes.
How Wegovy Differs From Ozempic
Wegovy and Ozempic both contain semaglutide and work identically inside your body. The key difference is dosage and intended use. Ozempic maxes out at 2 mg per week and is prescribed specifically to improve blood sugar in type 2 diabetes. Wegovy goes up to 2.4 mg per week as an injection (and up to 25 mg as a newer oral tablet) because the higher dose produces greater weight loss.
If your doctor is treating your diabetes, they’ll prescribe Ozempic. If the primary goal is weight loss, even if you happen to have diabetes, Wegovy is the designated option. Insurance coverage often follows these labels strictly, which is why the distinction matters in practice.
How Semaglutide Works in the Body
Semaglutide mimics a hormone your gut naturally releases after eating called GLP-1. This hormone does two things: it signals your pancreas to produce insulin (which lowers blood sugar), and it communicates with your brain to reduce appetite. At the higher doses used in Wegovy, the appetite-suppressing effects become more pronounced.
Research in animals has mapped out how semaglutide reaches the brain. It doesn’t cross the blood-brain barrier directly. Instead, it enters through a handful of specialized entry points near the brain’s ventricles and activates networks across at least 10 brain regions. These networks influence meal termination (the signal that tells you to stop eating), food reward (how pleasurable eating feels), and energy expenditure. The combined effect is that people on Wegovy feel full sooner, think about food less, and find it easier to eat smaller portions without feeling deprived.
The Heart Health Benefit
A large clinical trial called SELECT tested Wegovy in over 17,000 adults who had existing heart disease and were overweight or obese but did not have diabetes. Semaglutide at the 2.4 mg dose reduced the combined risk of heart attack, stroke, and cardiovascular death by 20% compared to placebo. This result led to Wegovy’s expanded approval for cardiovascular risk reduction, making it the first weight-loss medication to earn that label.
What Starting Wegovy Looks Like
Wegovy uses a gradual dose-escalation schedule to reduce side effects. You start at 0.25 mg once weekly for the first four weeks, then increase every four weeks through 0.5 mg, 1 mg, and 1.7 mg before reaching the maintenance dose of 1.7 mg or 2.4 mg from week 17 onward. Adolescents go directly to 2.4 mg as their maintenance dose. Each step up can bring a new wave of side effects, so if a particular dose is hard to tolerate, your prescriber may hold you at that level for an extra four weeks before moving up.
Common Side Effects
Gastrointestinal symptoms are by far the most frequent issue. Nausea, diarrhea, vomiting, constipation, and abdominal pain all occur in more than 5% of users. In adolescent trials, 62% of Wegovy-treated patients reported some type of GI complaint compared to 42% on placebo. Most of these symptoms are mild to moderate and improve as your body adjusts, particularly during the early dose-escalation phase.
Severe GI side effects affected about 4.1% of adults on Wegovy in clinical trials. Roughly 4.3% of patients discontinued treatment entirely because of stomach-related problems, with nausea (1.8%), vomiting (1.2%), and diarrhea (0.7%) being the most common reasons for stopping. Other reported side effects include headache, fatigue, dizziness, acid reflux, and hair loss.
People with type 2 diabetes who take Wegovy should be aware that hypoglycemia (low blood sugar) is listed as a common side effect in that population, especially if they’re also taking insulin or other glucose-lowering medications. Dose adjustments to existing diabetes drugs are sometimes necessary.
Who Qualifies for Wegovy
For adults, you need either a BMI of 30 or higher, or a BMI between 27 and 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol, type 2 diabetes, prediabetes, or obstructive sleep apnea. For the cardiovascular indication, you need established heart disease along with obesity or overweight. Adolescents aged 12 and older qualify if they meet the clinical definition of obesity for their age.
Having type 2 diabetes doesn’t disqualify you from Wegovy. It simply means your doctor is prescribing it for weight management rather than glucose control. Many people with diabetes benefit from both effects simultaneously, even though the label focuses on weight.